Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor‐experienced patients with hepatitis C: Real‐world data from a multicenter Asian registry
- DOI
- 10.60692/03hzq-tgf32
- Published
- 2022
- Container
- Not recorded
- Publisher
- OpenAlex
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.60692/03hzq-tgf32,
title = {Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor‐experienced patients with hepatitis C: Real‐world data from a multicenter Asian registry},
author = {Yu Jun Wong and Rahul Kumar and Rahul Kumar and Jessica Tan and Chih-en Liu and VW‐K Hui and Soek Siam Tan and Jia‐Horng Kao and Gtc Wong and Prem Harichander Thurairajah},
year = {2022},
doi = {10.60692/03hzq-tgf32},
url = {https://doi.org/10.60692/03hzq-tgf32}
}RIS
TY - JOUR TI - Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor‐experienced patients with hepatitis C: Real‐world data from a multicenter Asian registry AU - Yu Jun Wong AU - Rahul Kumar AU - Rahul Kumar AU - Jessica Tan AU - Chih-en Liu AU - VW‐K Hui AU - Soek Siam Tan AU - Jia‐Horng Kao AU - Gtc Wong AU - Prem Harichander Thurairajah PY - 2022 DO - 10.60692/03hzq-tgf32 UR - https://doi.org/10.60692/03hzq-tgf32 ER -
APA
Wong, Y. J., Kumar, R., Kumar, R., Tan, J., Liu, C., Hui, V., Tan, S. S., Kao, J., Wong, G., & Thurairajah, P. H. (2022). Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor‐experienced patients with hepatitis C: Real‐world data from a multicenter Asian registry. https://doi.org/10.60692/03hzq-tgf32